Abstract

The pancreatitis-associated protein I (PAP I) is a pancreatic secretory protein expressed in pancreas during acute pancreatitis but not in the healthy pancreas. The promoter of the PAP I gene thus represents a potential candidate to drive expression of therapeutic molecules to the diseased pancreas. In this work, we have constructed recombinant adenoviruses harboring the chloramphenicol acetyltransferase (CAT) gene driven by several fragments of the PAP I promoter and have characterized their properties in vitro and in vivo. In vitro studies showed that the transduction of the pancreatic cell line AR-42J with these adenoviruses led to low levels of CAT activity in basal conditions. After stimulation with a combination of interleukin-6 and dexamethasone or after induction of oxidative stress, CAT activity was strongly induced, a characteristic of the endogenous PAP I gene. Stimulation was maximal when constructs comprised 1253 base pairs of the PAP I promoter, upstream from initiation of transcription, and decreased with shorter fragments of 317, 180, 118 or 61 base pairs. The recombinant adenovirus containing the CAT gene under the control of the PAP I promoter fragment (-1253/+10) was also tested in vivo. Following administration by intravenous injection into mice, CAT activity was measured in several tissues 96 h later. In healthy animals, low but significant CAT activity was detected in pancreas, compared with near background values observed in the other tissues. When experimental acute pancreatitis was induced, CAT expression was strongly enhanced only in pancreas. In control experiments with adenoviruses in which the CAT gene was driven by the cytomegalovirus promoter, higher levels of expression were observed in all tissues. Expression was not modified after induction of acute pancreatitis. In conclusion, this study shows that (i) a recombinant adenovirus containing a fragment of the PAP I promoter allows specific targeting of a reporter gene to the mouse pancreas and (ii) expression of the reporter gene in pancreas is induced during acute pancreatitis. Adenovirus-mediated gene therapy of acute pancreatitis is therefore conceivable.

Highlights

  • Specific gene targeting into a diseased tissue is the main challenge of somatic gene therapy

  • This study shows that (i) a recombinant adenovirus containing a fragment of the pancreatitis-associated protein I (PAP I) promoter allows specific targeting of a reporter gene to the mouse pancreas and (ii) expression of the reporter gene in pancreas is induced during acute pancreatitis

  • In Vitro Reporter Gene Transfer to Pancreatic Cells—As a control to our experimental system, we evaluated the ability of the adenovirus vector containing the chloramphenicol acetyltransferase (CAT) gene driven by the ubiquitous CMV promoter to express in AR-42J cells the CAT enzyme activity

Read more

Summary

Introduction

Specific gene targeting into a diseased tissue is the main challenge of somatic gene therapy. This makes promoters of genes expressed during a disease (e.g. cancer, inflammation) interesting candidates to drive therapeutic genes to the diseased tissue. Expression of all PAP genes in the pancreas is strongly induced during the acute phase of pancreatitis [2,3,4]. PAP I, which is not detectable in the healthy pancreas, is among all PAPs the most strongly expressed during the acute phase of pancreatitis [6, 7]. The PAP I promoter is a potential candidate for specific gene transfer into the inflamed pancreas. We have tested its efficacy at driving the expression of a reporter gene, chloramphenicol acetyltransferase (CAT) in vitro and in vivo, using an adenovirus-mediated transfer system

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call